CatalystEU/UK

Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher

Novo Nordisk's 7% drop on competition fears outweighs Eli Lilly and Viking moves.

What changed

Novo Nordisk's 7% drop on competition fears outweighs Eli Lilly and Viking moves.

Why it matters

Novo Nordisk's 7% drop on competition fears outweighs Eli Lilly and Viking moves. — impact context not separately stored; see What changed.

Sources